

#53247

Date:

September 22, 2023

Subject: Adjusted Magenta Therapeutics, Inc. – Cash In Lieu Settlement Adjusted Option Symbol: DNTH1

Adjusted Dianthus Therapeutics, Inc. (formerly known as Magenta Therapeutics, Inc.) options were adjusted on September 12, 2023 (See OCC Information Memo #53164). The deliverable became 1) 6 Dianthus Therapeutics, Inc. (DNTH) Common Shares, and 2) Cash in lieu of 0.25 fractional DNTH Shares. Only settlement of the cash portion of DNTH1 options exercise/assignment activity was subject to delayed settlement.

OCC has been informed that a price of \$12.0816 per whole DNTH share will be used to determine the cash in lieu amount. Accordingly, the cash in lieu amount is:

0.25 x \$12.0816 = \$3.02 per DNTH1 Contract

Now that the exact cash in lieu amount has been determined, OCC will require Put exercisers and Call assignees, during the period of September 12, 2023 through September 22, 2023, to deliver the appropriate cash amount.

The cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

Terms of the DNTH1 options are as follows:

New Deliverable Per Contract:	1) 6 Dianthus Therapeutics, Inc. (DNTH) Common Shares 2) \$3.02 Cash
Strike Prices:	Unchanged
CUSIP:	DNTH: 252828108
Multiplier:	100 (i.e., a premium of 1.50 yields \$150)

<u>Settlement</u>

The DNTH component of DNTH1 exercise/assignment activity from September 12, 2023 through September 21, 2023, has settled through National Security Clearing Corporation (NSCC). The \$3.02 cash amount will be settled by OCC.

Pricing

The underlying price for DNTH1 will be determined as follows:

DNTH1 = 0.06 (DNTH) + 0.0302

For example, if DNTH closes at 13.11, the DNTH1 price would be calculated as follows:

DNTH1 =0.06 (13.11) + 0.0302 = 0.82

<u>Disclaimer</u>

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.